Condition: T-cell Prolymphocytic Leukemia · Refractory T-Cell Prolymphocytic Leukemia · Sponsor: M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.
This description comes directly from the study's public registry record.
Tapan Kadia, MD · (713) 563-3534 · tkadia@mdanderson.org
Always discuss trial participation with your own doctor first.
| The University of Texas M. D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07311746